AmpliPhi Biosciences announces first closing of $2.7m
AmpliPhi Biosciences Corporation has announced that is has closed on an initial amount of $2.7M in equity investment and convertible loan notes to support the further progress of the Company. In total, the Company is seeking up to $5m in this round.
This initial round was led by prominent private investors Jim Mellon and Gwynn Williams. Mr. Mellon, an investor with more than two decades of experience in fund management, is well known for his expertise in development economics. He is author of the books Wake Up! Survive and Prosper in the Coming Economic Turmoil, and Top Ten Investments to Beat the Crunch. Mr. Williams, a chartered physicist and fellow of the Institute of Physics in the UK, is founder of numerous biotech companies including, Xoma, Inc., BioMarin Pharmaceutical Inc., Glyko Biomedical Ltd. and its predecessor Glyko Inc., among many others.
The Company has also announced that it has opened a US-based research facility in Richmond, Virginia to facilitate US-based collaborations.
Philip J. Young, Chief Executive Officer said, “I am delighted that Ampliphi has been successful in securing additional investment into the Company. The quality and experience of Jim Mellon and Gwynn Williams represents an important endorsement of the potential of our technology.”
Other news from the department business & finance
